Insider Buying: Cue Biopharma Inc (NASDAQ:CUE) SVP Acquires 16,938 Shares of Stock

Cue Biopharma Inc (NASDAQ:CUE) SVP Colin Sandercock purchased 16,938 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were purchased at an average cost of $7.83 per share, with a total value of $132,624.54. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CUE opened at $8.60 on Thursday. Cue Biopharma Inc has a fifty-two week low of $4.16 and a fifty-two week high of $14.29. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.02 and a quick ratio of 3.02. The stock has a market cap of $171.25 million, a PE ratio of -4.43 and a beta of 1.17.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter. Cue Biopharma had a negative return on equity of 116.05% and a negative net margin of 3,233.51%. The firm had revenue of $0.37 million for the quarter.

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its holdings in shares of Cue Biopharma by 1,159.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock valued at $29,000 after acquiring an additional 3,503 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Cue Biopharma by 51.3% during the 4th quarter. Rhumbline Advisers now owns 22,795 shares of the company’s stock valued at $107,000 after acquiring an additional 7,724 shares during the last quarter. State of Wisconsin Investment Board increased its holdings in shares of Cue Biopharma by 30.3% during the 1st quarter. State of Wisconsin Investment Board now owns 24,100 shares of the company’s stock valued at $186,000 after acquiring an additional 5,600 shares during the last quarter. Raymond James & Associates acquired a new position in shares of Cue Biopharma during the 1st quarter valued at about $292,000. Finally, Sigma Planning Corp acquired a new position in shares of Cue Biopharma during the 1st quarter valued at about $325,000. 16.62% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2019/06/13/insider-buying-cue-biopharma-inc-nasdaqcue-svp-acquires-16938-shares-of-stock.html.

About Cue Biopharma

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Read More: Trading Penny Stocks

Insider Buying and Selling by Quarter for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.